HIGHLIGHTS
- What: The authors have developed a novel slow-release NP estrogen (SNP-E2) delivery system that shows sustained release of E2 in the injured spinal cord and no systemic exposure in the host. While this study is focused on the slow-release nanoparticle (NP) estrogen (SNP-E2) construct, the overall goal is to co-administer the slow-release nano-E2 (SNP-E2) which may increase availability of E2 and prolong the therapeutic effects of FNP-E2 to decrease inflammation in subacute and chronic phases of the SCI. This study is focused on SNP-E2. This study showed . . .

If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.